How Novo Nordisk A/S (ADR) (NVO) Will Deal With A Diabetes Delay: Sanofi SA (ADR) (SNY), Johnson & Johnson (JNJ)

Page 1 of 2

Novo Nordisk A/S (ADR) (NYSE:NVO) recently got some bad news from the Food and Drug Administration: a request for additional information about a key insulin product. That notice could delay the new treatment’s launch until at least 2015 — a big delay, but one the company can probably handle.

Novo Nordisk A/S (ADR) (NYSE:NVO)Novo Nordisk

Novo Nordisk started treating people with insulin in 1923. Today, insulin is the company’s core market, with a 49% share of the world market based on volume. While the company has other areas on which it focuses, including hemophilia and weight loss (intimately tied to diabetes and insulin), it derives nearly 80% of its revenues from its diabetes business. Insulin, then, is ultra-important to Novo’s long-term success.

This market holds great opportunity, too. For example, the company believes that there are over 370 million people with diabetes in the world today. It expects that number to increase to 550 million by 2030. The United States is one of the leading markets, largely because of an aging and increasingly overweight population, factors that increase the incidence of type 2 diabetes. China, however, is an up-and-coming market for the Novo as well.

Novo Nordisk A/S (ADR) (NYSE:NVO) estimates that there are over 90 million people in China with diabetes, making it the world’s largest diabetes market. Interestingly, the same reasons that have made the United States such an important market are increasingly hurting Chinese citizens. “With economic growth comes urbanisation, with urbanisation come sedentary lifestyles – and then diabetes follows.” Management estimates that 90% of people with diabetes have type 2.

Less Shots

The big pushes in diabetes research are to reduce the number of times that a diabetic has to medicate, and to improve the medication delivery method. Injection is the main method for getting insulin into the body. Clearly, that’s not a desirable approach, so reducing the number of times that a patient has to inject themselves, or completely altering the way in which insulin is delivered, would be a huge benefit and likely lead to a blockbuster drug.

This is where the company’s once-a-day Tresiba comes into play. The drug has been approved in Japan, Mexico, and in the European Union. However, in early 2013, the FDA chose not to approve the drug, asking instead for additional research into Tresiba’s potential cardiovascular risks.

A Big Hit

After receiving approval in the other markets, the FDA’s decision came as something of a shock to the market. At one point following the news, Novo Nordisk’s shares were down as much as 17%. While the shares rebounded from those depths, the announcement sent the shares notably lower.



NVO data by YCharts

Providing the research to the FDA will be expensive and time-consuming. In fact, Reuters reported that Novo’s Chief Scientific Officer, Mads Thomsen, said that the company probably wouldn’t be able to provide the information until after 2014. Some market watchers estimate that even 2015 could be an aggressive expectation. A multi-year delay is clearly not a good thing for the company’s prospects, since the U.S. market is so important to its business.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!